We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cobra Bio-Man. | LSE:CBF | London | Ordinary Share | GB0031704835 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Cobra Bio-Manufacturing PLC 12 November 2003 For Immediate Release 12 November 2003 Cobra Biomanufacturing Plc COBRA GRANTED KEY EUROPEAN PATENT FOR DNA MANUFACTURE Keele, UK: Cobra Biomanufacturing Plc (AIM:CBF), the international manufacturer of biopharmaceuticals, announces today the grant of the European Patent 1159062. from the European Patent Office. This patent relates to the large-scale manufacture of plasmid DNA medicines and vaccines and covers Cobra's unique device and methods for extraction and purification. DNA products are complex and extremely difficult to manufacture at the high levels of scalability required for commercialisation and to the rigorous quality standards required by the regulatory authorities. The market for DNA medicines and vaccines is set to grow to in excess of $4 billion by the end of the decade. Cobra's leading position in plasmid DNA and the manufacture of other high value, high potency biopharmaceutical products is maintained by continued innovation and investment in novel manufacturing technologies. David Thatcher, Chief Executive of Cobra, said: "Cobra provides DNA manufacturing services which are second to none, our ability to offer this service is dependent on our commitment to innovation and the development of technology led manufacturing solutions. The grant of this patent in Europe is another important step forward in consolidating Cobra's position as the leading manufacturer of plasmid DNA medicines and vaccines." - ENDS - For further information please contact: David Thatcher, CEO Cobra + 44 (0) 1782 714 181 Tim Anderson/Rebecca Dietrich Buchanan Communications + 44 (0) 207 466 5000 Notes to Editors Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business. Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising #7 million and raised a further #5.25 million in May 2003 in order to further expand capacity in Oxford UK. Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', ' will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', ' estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research, which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue. This information is provided by RNS The company news service from the London Stock Exchange END NRAKGMMMNMMGFZM
1 Year Cobra Bio-manufacturing Chart |
1 Month Cobra Bio-manufacturing Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions